Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

AIDS

Volumn 15, Issue 18, 2001, Pages 2407-2414

  Van der Valk, M ^a   Kastelein, J J P ^a   Murphy, R L ^a   Van Leth, F ^a   Katlama, C ^a   Horban, A ^a   Glesby, M ^a   Behrens, G ^a   Clotet, B ^a   Stellato, R K ^a   Molhuizen, H O F ^a   Reiss, P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Coronary artery disease; High density lipoprotein; HIV; Hyperlipidemia; Nevirapine

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA;

ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035824764     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200112070-00008     Document Type: Article

References (32)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
3. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
4. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
5. Coronary artery disease and human immunodeficiency virus infection
6. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
7. Severe premature coronary artery disease with protease inhibitors
8. Vascular complications associated with use of HIV protease inhibitors
9. Vascular complications associated with use of HIV protease inhibitors
10. Vascular complications associated with use of HIV protease inhibitors
11. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
12. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
13. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study
14. High density lipoprotein cholesterol and mortality. The Framingham Heart Study
15. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular Munster study
16. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki heart study
17. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study
18. Preliminary results of anthropometric and metabolic changes observed in HIV-infected patients treated with combivir plus nelfinavir or nevirapine (a substudy of the COMBINE-study)
19. The Atlantic Study: A randomized, open-labeled trial comparing two protease inhibitor (PI)-sparing anti-retroviral strategies versus a standard PI-containing regimen, final 48 week data
20. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
21. The Atlantic study: A randomized, open-labeled trial comparing two protease inhibitor (PI)-sparing anti-retroviral strategies versus a standard PI-containing regimen, final 48 week data
22. Reverse cholesterol transport - A review of the process and its clinical implications
23. Paraoxonase genes and disease
24. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
25. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis
26. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
27. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice
28. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
29. Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: Results of the VA-HIT study
30. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables
31. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction
32. Significantly improved cardiovascular risk profile in women who switch from a protease inhibitor to efavirenz